TD Cowen analyst Yaron Werber has maintained their bullish stance on STOK stock, giving a Buy rating on April 22.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yaron Werber has given his Buy rating due to a combination of factors, including strong clinical execution in the EMPEROR Phase 3 trial and encouraging long-term data from earlier studies. Enrollment is advancing quickly, with most patients already in the study and no discontinuations reported, which supports a clear path toward a mid-2027 data readout and potential late-2027 or early-2028 approval.
In addition, four-year open-label extension results show durable functional gains and a favorable safety profile, reinforcing confidence that zorevunersen could deliver meaningful benefit in Dravet syndrome. The company’s substantial $411 million cash position provides funding through 2028, covering Phase 3 completion, regulatory submission, and an initial U.S. launch, leading Werber to view the current valuation as offering attractive risk versus potential reward.
In another report released on April 22, H.C. Wainwright also maintained a Buy rating on the stock with a $50.00 price target.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STOK in relation to earlier this year.